Clinical trials
Phase 4 Stroke trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 4 |
| 2010 | 3 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Unknown status | 13 |
| Recruiting | 6 |
| Not yet recruiting | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| General Hospital of Shenyang Military Region | 3 |
| Beijing Tiantan Hospital | 2 |
| China Academy of Chinese Medical Sciences | 2 |
| Chinese Academy of Medical Sciences, Fuwai Hospital | 2 |
| Guangzhou University of Traditional Chinese Medicine | 2 |
| Peking Union Medical College Hospital | 2 |
| Sir Run Run Shaw Hospital | 2 |
| Yong Jiang | 2 |
| Beijing Anzhen Hospital | 1 |
| Boehringer Ingelheim | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stroke | 40 |
| Ischemic Stroke | 9 |
| Atrial Fibrillation | 4 |
| Cardiovascular Diseases | 4 |
| Hypertension | 4 |
| Myocardial Infarction | 4 |
| Hemorrhage | 3 |
| Atherosclerosis | 2 |
| Embolism and Thrombosis | 2 |
| Mitral Valve Insufficiency | 2 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.